Cellular therapy and precision diagnostics developer Avalon GloboCare (Avalon) has reached an exclusive distribution agreement with medical device company Qi Diagnostics.

Under the deal, Avalon will exclusively supply Qi Diagnostics’ KetoAir breathalyser device and related accessories including current and future models in the UK, the European Union, North America and South America.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

KetoAir can be used as a companion diagnostic as well as a monitoring device for people who follow a ketogenic diet.

Approved by the US Food and Drug Administration (FDA), KetoAir is incorporated with artificial intelligence nutritionist consultation for ketogenic health management.

Avalon president and CEO Dr David Jin said: “Being able to safely and consistently maintain nutritional ketosis has been shown to increase the chances of diabetes reversal.

“KetoAir is the first breathalyser on the market that uses an artificial intelligence nutritionist bundled with the nanosensor-based breathalyser for ketogenic health management.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“It can detect and quantify acetone levels in the breath and monitor the ketosis state while also providing 24/7 nutritional advice. We look forward to commercialising KetoAir and helping those individuals with diabetes and weight-management needs.”

Avalon will initially focus on selling KetoAir devices for the diabetes reversal and weight-management markets.

Furthermore, the companies will work together on the development of a breathalyser device to screen and detect early-stage lung cancer.

They will jointly own any intellectual property achieved through the co-development of lung cancer breathalyser products.

A definitive agreement is expected to be signed to fix the final terms and pricing.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact